Davern Capital Partners, LP 13F: Quarter-over-Quarter Portfolio Changes
Davern Capital Partners, LP reported a disclosed portfolio value of approximately $364.5 million in its latest SEC Form 13F-HR filing for Q1 2026, up 17.9% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 7 holdings, trimmed 6 holdings, and exited 1 position.
Davern Capital Partners, LP's top buy was a new stake in Insmed INC (INSM) , equal to 8.2% of the disclosed portfolio. Its top sell was Royalty Pharma PLC (RPRX) . The fund sold 38.1% of its previously reported shares, reducing the position's portfolio weight by 3.7 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| INSMED INC | INSM | 8.2% | History → |
| GENERATE BIOMEDICINES INC | GENB | 2.0% | Holders → |
| PROCEPT BIOROBOTICS CORP | PRCT | 1.8% | Holders → |
| STRUCTURE THERAPEUTICS INC | GPCR | 1.7% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| ELI LILLY & CO | LLY | +4.0% | +228.4% | History → |
| MINERALYS THERAPEUTICS INC | MLYS | +0.9% | +112.3% | Holders → |
| NATERA | NTRA | +2.1% | +83.0% | History → |
| IONIS PHARMACEUTICALS INC | IONS | +1.9% | +62.2% | History → |
| ABIVAX SA | ABVX | +0.3% | +61.1% | Holders → |
| LEGEND BIOTECH CORP | LEGN | +-0.9% | +24.4% | Holders → |
| VIRIDIAN THERAPEUTICS INC | VRDN | +-1.0% | +15.6% | Holders → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| ROYALTY PHARMA PLC | RPRX | -3.7% | 38.1% | History → |
| PFIZER | PFE | -4.2% | 22.0% | History → |
| BIONTECH SE | BNTX | -4.0% | 17.8% | History → |
| ROIVANT SCIENCES LTD | ROIV | -0.6% | 15.1% | History → |
| REGENERON PHARMACEUTICALS | REGN | -3.6% | 14.5% | History → |
| ARGENX SE | ARGX | -2.7% | 1.8% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CG ONCOLOGY INC | CGON | 2.2% |
Net Portfolio Value ChangeQ1 2026
- $0.3BPrior quarter
- $0.4BCurrent quarter
- +$0.1BNet delta
- +17.9%% change
Methodology & FAQ
How Davern Capital Partners, LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Davern Capital Partners, LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Davern Capital Partners, LP buy in Q1 2026?
In Q1 2026, Davern Capital Partners, LP initiated 4 new positions (INSMED INC (INSM), GENERATE BIOMEDICINES INC (GENB), PROCEPT BIOROBOTICS CORP (PRCT), STRUCTURE THERAPEUTICS INC (GPCR)); bought more shares of ELI LILLY & CO (LLY), MINERALYS THERAPEUTICS INC (MLYS), NATERA (NTRA), IONIS PHARMACEUTICALS INC (IONS), ABIVAX SA (ABVX) — the largest 5 of 7 adds.
What stocks did Davern Capital Partners, LP sell in Q1 2026?
In Q1 2026, Davern Capital Partners, LP fully sold 1 position (CG ONCOLOGY INC (CGON)); reduced holdings in ROYALTY PHARMA PLC (RPRX), PFIZER (PFE), BIONTECH SE (BNTX), ROIVANT SCIENCES LTD (ROIV), REGENERON PHARMACEUTICALS (REGN) — the largest 5 of 6 reductions.
Which positions did Davern Capital Partners, LP initiate in Q1 2026?
Davern Capital Partners, LP established 4 new positions in Q1 2026: INSMED INC (INSM, 8.2%), GENERATE BIOMEDICINES INC (GENB, 2.0%), PROCEPT BIOROBOTICS CORP (PRCT, 1.8%), STRUCTURE THERAPEUTICS INC (GPCR, 1.7%).
Which existing positions saw the largest allocation increases for Davern Capital Partners, LP in Q1 2026?
Of 7 existing positions with share-count increases in Q1 2026, the largest were: ELI LILLY & CO (LLY, +4.0% weight, +228.4% shares), MINERALYS THERAPEUTICS INC (MLYS, +0.9% weight, +112.3% shares), NATERA (NTRA, +2.1% weight, +83.0% shares), IONIS PHARMACEUTICALS INC (IONS, +1.9% weight, +62.2% shares), ABIVAX SA (ABVX, +0.3% weight, +61.1% shares), LEGEND BIOTECH CORP (LEGN, +-0.9% weight, +24.4% shares), VIRIDIAN THERAPEUTICS INC (VRDN, +-1.0% weight, +15.6% shares).
Which positions did Davern Capital Partners, LP fully exit in Q1 2026?
Davern Capital Partners, LP fully exited 1 position in Q1 2026: CG ONCOLOGY INC (CGON, last-reported weight 2.2%).
Which existing positions saw the largest allocation reductions for Davern Capital Partners, LP in Q1 2026?
Of 6 existing positions with share-count reductions in Q1 2026, the largest were: ROYALTY PHARMA PLC (RPRX, -3.7% weight, -38.1% shares), PFIZER (PFE, -4.2% weight, -22.0% shares), BIONTECH SE (BNTX, -4.0% weight, -17.8% shares), ROIVANT SCIENCES LTD (ROIV, -0.6% weight, -15.1% shares), REGENERON PHARMACEUTICALS (REGN, -3.6% weight, -14.5% shares), ARGENX SE (ARGX, -2.7% weight, -1.8% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.